Interdisziplin?re und individualisierte Therapie des Prostatakarzinoms

详细信息    查看全文

• 作者：M. Schwardt ; J. Debus ; G. Feick ; B. Hadaschik ; M. Hohenfellner ; R. Schüle…
• 关键词：Therapie ; stadiengerechte ; Risikostratifizierung ; Radiotherapie ; Therapie ; chirurgische ; Tumorsubklassifizierung ; Therapy ; stage ; oriented ; Risk stratification ; Radiotherapy ; Therapy ; operative ; Subclassification ; tumors
• 刊名：Der Urologe A
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：54
• 期：11
• 页码：1584-1590
• 全文大小：493 KB
• 参考文献：1.Schroder FH, Hugosson J, Roobol MJ et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981-90CrossRef PubMed
  2.Brett AS, Ablin RJ (2011) Prostate-cancer screening -what the U.S. Preventive Services Task Force left out. N Engl J Med 365(21):1949-951CrossRef PubMed
  3.McNaughton-Collins MF, Barry MJ (2011) One man at a time -resolving the PSA controversy. N Engl J Med 365(21):1951-953CrossRef PubMed
  4.Schroder FH (2011) Stratifying risk -the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 365(21):1953-955CrossRef PubMed
  5.Budaus L, Spethmann J, Isbarn H et al (2011) Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 108(8):1256-261CrossRef PubMed
  6.Djulbegovic M, Beyth RJ, Neuberger MM et al (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:4543CrossRef
  7.Eichler K, Hempel S, Wilby J et al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605-612CrossRef PubMed
  8.Roethke MC, Kuru TH, Afshar-Oromieh A et al (2013) Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur Urol 64(5):862-64CrossRef PubMed
  9.Afshar-Oromieh A, Zechmann CM, Malcher A et al (2013) Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 40(10):1629-630CrossRef PubMed
  10.Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652-64CrossRef PubMed
  11.Weischenfeldt J, Simon R, Feuerbach L et al (2013) Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2):159-70CrossRef PubMed
  12.Cuevas R, Korzeniewski N, Tolstov Y et al (2013) FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Res 73(4):1400-410CrossRef PubMed
  13.Korzeniewski N, Hohenfellner M, Duensing S (2012) CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia 14(9):799-06PubMedCentral CrossRef PubMed
  14.Prensner JR, Iyer MK, Balbin OA et al (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742-49PubMedCentral CrossRef PubMed
  15.Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52):21276-1281PubMedCentral CrossRef PubMed
  16.Kannan K, Wang L, Wang J et al (2011) Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 108(22):9172-177PubMedCentral CrossRef PubMed
  17.Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16(4):1088-093PubMedCentral CrossRef PubMed
  18.Metzger E, Imhof A, Patel D et al (2010) Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464(7289):792-96CrossRef PubMed
  19.Huber J, Herpel E, Jakobi H et al (2012) Two decades-experience with a prospective biobank for urologic oncology: research, clinical care, and the patients-view. Urol Oncol 33(2):97-10
  20.Hatiboglu G, Pinkawa M, Vallee JP et al (2012) Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 110(11 Pt B):647-52CrossRef
  21.Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233-239CrossRef PubMed
  22.Minniti D, Chiado Piat S, Di Novi C (2011) Robot-assisted versus open radical prostatectomy: an evidence-based comparison. Technol Health Care 19(5):331-39PubMed
  23.Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr (2012) Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 30(5):513-18PubMedCentral CrossRef PubMed
  24.Asimakopoulos AD, Pereira Fraga CT, Annino F et al (2011) Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 8(5):1503-512CrossRef PubMed
  25.Montague DK (2005) Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy. Rev Urol 7(Suppl 2):51-7
  26.Zelefs
• 作者单位：M. Schwardt (1)
  J. Debus (2)
  G. Feick (4)
  B. Hadaschik (3)
  M. Hohenfellner (3)
  R. Schüle (1)
  J.-P. Zacharias (4)
  Prof. Dr. S.E. Combs (2) (5)
  
  1. Urologie, Universit?tsklinikum Freiburg, Freiburg, Deutschland
  2. RadioOnkologie und Strahlentherapie, Universit?tsklinikum Heidelberg, Heidelberg, Deutschland
  4. Bundesverband Prostatakrebs Selbsthilfe e.V., Gehrden, Deutschland
  3. Urologische Universit?tsklinik Heidelberg, Heidelberg, Deutschland
  5. Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Technische Universit?t München (TUM), Klinikum Rechts der Isar, Ismaninger Stra?e 22, 81675, München, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0563

文摘

Multimodal treatment of prostate cancer is based on specific staging via imaging, clinical parameters, tumor markers and histopathological grading. Risk-adapted therapy encompasses wait and see, active surveillance, surgical intervention, radiotherapy and hormone therapy. Some patients also need a combination of these treatment options. Even though clinical parameters guide the treatment plan, patient wishes and preferences are incorporated. Against this background leading basic research scientists, urologists, radiotherapists, epidemiologists and members of other associated disciplines discussed state of the art treatment concepts, innovative trial designs and translational research projects at the international meeting ?Challenges and Chances in Prostate Cancer Research-organized by the German Cancer Aid (Deutsche Krebshilfe). Keywords Therapy, stage-oriented Risk stratification Radiotherapy Therapy, operative Subclassification, tumors